TITLE

Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

AUTHOR(S)
Mori, T.; Mori, S.; Kanda, Y.; Yakushiji, K.; Mineishi, S.; Takaue, Y.; Gondo, H.; Harada, M.; Sakamaki, H.; Yajima, T.; Iwao, Y.; Hibi, T.; Okamoto, S.
PUB. DATE
February 2004
SOURCE
Bone Marrow Transplantation;Feb2004, Vol. 33 Issue 4, p431
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary:To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CMV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.Bone Marrow Transplantation (2004) 33, 431-434. doi:10.1038/sj.bmt.1704369 Published online 15 December 2003
ACCESSION #
12185608

 

Related Articles

  • Utility of antigenemia test for cytomegalovirus detection in hematopoietic transplant recipients: report of experiences from Medellin, Colombia. Sarmiento-Maldonado, M; Eugenia Castano-Orozco, M; Bedoya-Escobar, V I; Calle-Fernandez, S; Velasquez-Lopera, M; Gomez-Wolff, R; Karduss Urueta, A; Cuellar-Ambrosi, F // Bone Marrow Transplantation;Jul2003, Vol. 32 Issue 1, p119 

    Presents a study that investigated the use of the antigenemia pp65 test for the diagnosis of cytomegalovirus (CMV) infection in hematopoietic stem-cell transplant recipients at a hospital in Medellín, Colombia. Background on the blood samples used in the study; Analysis of the treatment...

  • Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Moretti, S; Zikos, P; Van Lint, M T; Tedone, E; Occhini, D; Gualandi, F; Lamparelli, T; Mordini, N; Berisso, G; Bregante, S; Bruno, B; Bacigalupo, A // Bone Marrow Transplantation;7/15/98, Vol. 22 Issue 2, p175 

    This trial was designed to compare foscarnet with ganciclovir as pre-emptive therapy for CMV infection in patients undergoing allogeneic hemopoietic stem cell transplant (HSCT). Thirty-nine patients were randomized to receive foscarnet 90 mg/kg every 12 h (n = 20) or ganciclovir 5 mg/kg every 12...

  • Virological, Clinical, and Ophthalmologic Features of Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation. Crippa, Fulvio; Corey, Lawrence; Sale, George; Boeckh, Michael; Chuang, Elaine L. // Clinical Infectious Diseases;1/15/2001, Vol. 32 Issue 2, p214 

    Presents information on a study which examined the prevalence of cytomegalovirus retinitis in hematopoietic stem cell transplantation patients in Seattle, Washington. Methodology; Results of the study; Discussion.

  • Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. Kato, Ruri; Tamaki, Hiroya; Ikegame, Kazuhiro; Yoshihara, Satoshi; Kaida, Katsuji; Taniguchi, Kyoko; Inoue, Takayuki; Ishii, Shinichi; Nakata, Jun; Fujioka, Tatsuya; Eguchi, Ryoji; Soma, Toshihiro; Okada, Masaya; Ogawa, Hiroyasu // Annals of Hematology;Oct2015, Vol. 94 Issue 10, p1707 

    Human leukocyte antigen (HLA)-haploidentical stem cell transplantation (haplo-SCT) is associated with a high incidence of cytomegalovirus (CMV) infection, probably originating from the delayed reconstitution of CMV-specific T cell immunity. There have been few reports on the presence of...

  • Foscarnet.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p19 

    An abstract of the article "UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease," by K. Gregg and colleagues is presented.

  • Ganciclovir.  // Reactions Weekly;Jun2015, Vol. 1554 Issue 1, p94 

    An abstract of the article "Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping," by E. Drouot is presented.

  • Evaluation of the Validity of Preemptive Therapy against Cytomegalovirus Disease Based on Antigenemia Assay with a Cutoff of 20 Positive Cells per Two Slides. Sakamoto, Kana; Nakasone, Hideki; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Kawamura, Koji; Ashizawa, Masahiro; Sato, Miki; Terasako-Saito, Kiriko; Machishima, Tomohito; Kimura, Shun-Ichi; Kikuchi, Misato; Kako, Shinichi; Kanda, Junya; Yamazaki, Rie; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background:Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT). However, the appropriate threshold of antigenemia-positive cells for...

  • Mast cells: innate attractors recruiting protective CD8 T cells to sites of cytomegalovirus infection. Podlech, Jürgen; Ebert, Stefan; Becker, Marc; Reddehase, Matthias; Stassen, Michael; Lemmermann, Niels // Medical Microbiology & Immunology;Jun2015, Vol. 204 Issue 3, p327 

    Reactivation of latent cytomegalovirus (CMV) in the transient immunocompromised state after hematoablative treatment is a major concern in patients undergoing hematopoietic cell transplantation (HCT) as a therapy of hematopoietic malignancies. Timely reconstitution of antiviral CD8 T cells and...

  • Dasatinib: Cytomegalovirus colitis: case report.  // Reactions Weekly;6/29/2019, Vol. 1759 Issue 1, p85 

    The article describes the case of a patient who was cytomegalovirus (CMV) seropositive and developed CMV colitis while taking dasatinib for unspecified haematological malignancies, referencing a study by D. Prestes et al, published in "Open Forum Infectious Diseases."

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics